MedPath

Cevimeline Hydrochloride

Cevimeline Hydrochloride Capsules Rx only

Approved
Approval ID

d08d8aa5-76a4-417a-a308-7d195865522f

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 19, 2023

Manufacturers
FDA

Aurobindo Pharma Limited

DUNS: 650082092

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Cevimeline Hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code59651-422
Application NumberANDA215056
Product Classification
M
Marketing Category
C73584
G
Generic Name
Cevimeline Hydrochloride
Product Specifications
Route of AdministrationORAL
Effective DateJuly 2, 2022
FDA Product Classification

INGREDIENTS (9)

CEVIMELINE HYDROCHLORIDEActive
Quantity: 30 mg in 1 1
Code: P81Q6V85NP
Classification: ACTIR
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
HYDROXYPROPYL CELLULOSE (90000 WAMW)Inactive
Code: UKE75GEA7F
Classification: IACT
GELATIN, UNSPECIFIEDInactive
Code: 2G86QN327L
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
SHELLACInactive
Code: 46N107B71O
Classification: IACT
POTASSIUM HYDROXIDEInactive
Code: WZH3C48M4T
Classification: IACT
FERROSOFERRIC OXIDEInactive
Code: XM0M87F357
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Cevimeline Hydrochloride - FDA Drug Approval Details